Table 2.
Demographics of ODMT patients
| Total | FTY | DMF | TFN | P-value (3 groups) | |
|---|---|---|---|---|---|
| (N = 293) | (N = 101) | (N = 133) | (N = 59) | ||
| Female, n (%) | 214 (73.0) | 75 (74.3) | 96 (72.2) | 43 (72.9) | 0.9386 |
| Mean age, y (SD) | 48.0 (10.7) | 44.2 (10.7) | 49.6 (10.3) | 50.6 (9.6) | <0.0001 |
| Age group, n (%) | 0.0349 | ||||
| 18–24 years | 2 (0.7) | 2 (2.0) | 0 | 0 | |
| 25–34 years | 33 (11.3) | 18 (17.8) | 12 (9.1) | 3 (5.1) | |
| 35–44 years | 81 (27.7) | 34 (33.7) | 32 (24.2) | 15 (25.4) | |
| 45–54 years | 100 (34.3) | 31 (30.7) | 49 (37.1) | 20 (33.9) | |
| 55–64 years | 59 (20.2) | 12 (11.9) | 29 (22.0) | 18 (30.5) | |
| 65–74 years | 13 (4.5) | 4 (4.0) | 7 (5.3) | 2 (3.4) | |
| 75+ years | 4 (1.4) | 0 | 3 (2.3) | 1 (1.7) | |
| Missing | 1 (0.3) | 0 | 0 | 0 | |
| Region, n (%) | <0.0001 | ||||
| Midwest | 73 (25.1) | 32 (32.3) | 37 (27.8) | 4 (6.8) | |
| Northeast | 58 (19.9) | 24 (24.2) | 26 (19.6) | 8 (13.6) | |
| South | 105 (36.1) | 42 (42.4) | 37 (27.8) | 26 (44.1) | |
| West | 55 (18.9) | 1 (1.0) | 33 (24.8) | 21 (35.6) | |
| Missing | 2 (0.7) | 0 | 0 | 0 | |
| Race, n (%) | 0.0074 | ||||
| White | 61 (21.1) | 29 (28.7) | 28 (21.5) | 4 (6.9) | |
| Black | 11 (3.8) | 7 (6.9) | 1 (0.8) | 3 (5.2) | |
| Other | 3 (1.0) | 1 (1.0) | 1 (0.8) | 1 (1.7) | |
| Unknown | 214 (74.1) | 64 (63.4) | 100 (76.9) | 50 (86.2) | |
| Missing | 4 (1.4) | 0 | 0 | 0 | |
| Insurance, n (%) | 0.0051 | ||||
| Commercial | 70 (24.1) | 15 (15.0) | 35 (26.5) | 20 (34.5) | |
| Medicaid | 8 (2.8) | 0 | 6 (4.6) | 2 (3.5) | |
| Medicare | 28 (9.7) | 4 (4.0) | 16 (12.1) | 8 (13.8) | |
| Cash | 2 (0.7) | 1 (1.0) | 1 (0.8) | 0 | |
| Other | 5 (1.7) | 2 (2.0) | 3 (2.3) | 0 | |
| Unknown | 177 (61.0) | 78 (78.0) | 71 (53.8) | 28 (48.3) | |
| Missing | 3 (1.0) | 0 | 0 | 0 |
DMF dimethyl fumarate, ODMT oral disease-modifying therapy, FTY fingolimod, TFN teriflunomide